AzTrials
AzTrials

PancytopeniaNCT05473650

Spectrum of Hematological Disorders in Pediatrics

An observational study of Pancytopenia, run by Assiut University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

To determine the spectrum of pancytopenia with its frequency and etiology in children presenting to Assiut University Children Hospital during one year Read more about this study

Who is it for?
Ages 28 days to 18 years
Conditions the study is for
Pancytopenia
What is being tested?
CBC.with with differential Peripheral smear
How many people
100 participants
Where
No sites listed yet
Study dates
1 Sep 2022to 1 Nov 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 28 days to 18 years
  • All sexes
  • Child, Adult

Study population: patients with pancytopenia from the age of one month to 18 years old

Who may be able to join

  • All patients with presistant pancytopenia from age 1 month to 18 years at Assiut university hospital of pediatrics

Who cannot join

  • Patients below age of 1 month or above 18 years

Trial locations and contacts

No sites are listed yet.

zakria younes mohammed, resident doctor contact

01121224119

zakriaessemy@gmail.com

About this study

Official title: A Spectrum of Hematological Disorders in Children Presented With Pancytopenia at Assiut University Hospital

To determine the spectrum of pancytopenia with its frequency and etiology in children presenting to Assiut University Children Hospital during one year

Read the detailed description

Pancytopenia is a condition in which there is a decrease of all the three cellular elements of blood, namely erythrocytes, leukocytes, and platelets . It is quite a common finding among children. According to regional studies, it makes up around 2.90% to 3.57% of the burden of presentations in the pediatric population. Some of the presenting symptoms include, but are not limited to, pallor, fever, weight loss, dyspnea, bleeding, bruising, visceromegaly, and increased risk of infections .

Pancytopenia is not a disease in itself but a laboratory finding of the constitution of diseases. It can occur due to a variety of disorders which can be as simple as nutritional deficiencies to serious malignant disorders . Megaloblastic anemia and acute lymphoblastic leukemia are among the most common presentations of pancytopenia.

Pancytopenia results in a hypoplastic bone marrow. It is diagnosed on the basis of the complete blood count test. Pancytopenia is labeled when the hemoglobin (hb) is less than 10 gm%, absolute neutrophil count (anc) is less than 1.5*109/l, and platelet count is less than 100*109/l [9].

But, in order to find out the etiological factor causing pancytopenia, bone marrowexamination is done. Being an interventional procedure, it is relatively safe with little or no risk of bleeding.

Etiology of pancytopenia The etiology of pancytopenia can be broadly categorized as a central type that involves disorders of production or a peripheral type that involves disorders of increased destruction.These causes could contribute to the pancytopenia independently or as a combination.

Decreased production (central type): Pancytopenia due to decreased production is mostly secondary to nutritional deficiencies. Pancytopenia caused by bone marrow failure is known as aplastic anemia. Aplastic anemia could be idiopathic/autoimmune, secondary to infections (such as parvovirus B19, hepatitis, human immunodeficiency virus (HIV), cytomegalovirus, or Epstein-Barr virus), after drug toxicity, or chemotherapeutic agents (methotrexate, dapsone, carbimazole, carbamazepine, chloramphenicol). Pancytopenia can also be related to inadequate intake (as seen in eating disorders and alcoholics) or malabsorption.The production of cell lines is also impaired when the bone marrow is infiltrated by malignancies (lymphoma, leukemia, multiple myeloma) or granulomatous disorders. Metastatic tumors can also cause bone marrow replacement late in the disease, thus producing pancytopenia.

Increased destruction (peripheral type): Peripheral destruction of cells can be associated with many autoimmune conditions (such as systemic lupus erythematosus, rheumatoid arthritis) and splenic sequestration (alcoholic liver cirrhosis, HIV, tuberculosis, malaria). Hypersplenism affects more frequently the platelets and erythrocytes than leukocytes.

Differential diagnosis Multiple conditions can present with pancytopenia; hence, when someone shows with pancytopenia, a complete evaluation is performed to detect the cause of pancytopenia. Bone marrow disorders such as aplastic anemia, myelodysplastic syndrome, acute leukemia, myelofibrosis, megaloblastic anemia, paroxysmal nocturnal hemoglobinuria, and Fanconi's anemia can present with pancytopenia. Fanconi anemia is the most common congenital cause of bone marrow failure with an autosomal recessive inheritance pattern. In myelofibrosis, there is a replacement of the bone marrow cells with fibrotic tissue. Malignancies such as lymphoma, multiple myeloma, and hairy cell leukemia can also present with pancytopenia. Non-bone marrow conditions present with pancytopenia include systemic lupus erythematosus, infections (such as parvovirus B19, Epstein Barr virus, HIV, hepatitis, leishmaniasis, tuberculosis, malaria, and histoplasmosis).

Conditions
Pancytopenia
Being tested
CBC.with with differential Peripheral smear
Medical subject headings
Pancytopenia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CBC.with with differential Peripheral smearDiagnostic test

    determine spectrum of hematological disorders in childern with pancytopenia

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. percentage of aplastic anemia among other causes of pancytopenia in childern presented to assiut university childern hospital with abnormal CBC

    getting a proper diagnosis of different cases of pancytopeina in childern which helps in their treatment

    Measured: one year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Jul 2022
  2. Study start1 Sep 2022 (estimated)
  3. Primary completion30 Sep 2023 (estimated)
  4. Study completion1 Nov 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05473650
Sponsor's protocol ID
pancytopenia in pediatrics
Status last verified
Jul 2022
First submitted
19 Jul 2022
Last updated
26 Jul 2022
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Memon S, Shaikh S, Nizamani MA. Etiological spectrum of pancytopenia based on bone marrow examination in children. J Coll Physicians Surg Pak. 2008 Mar;18(3):163-7.

    PubMed 18460245
  • Sharma R, Nalepa G. Evaluation and Management of Chronic Pancytopenia. Pediatr Rev. 2016 Mar;37(3):101-111; quiz 112-3. doi: 10.1542/pir.2014-0087. No abstract available.

    PubMed 26933225
  • Das Makheja K, Kumar Maheshwari B, Arain S, Kumar S, Kumari S, Vikash. The common causes leading to pancytopenia in patients presenting to tertiary care hospital. Pak J Med Sci. 2013 Sep;29(5):1108-11. doi: 10.12669/pjms.295.3458.

    PubMed 24353701
  • Zeb Jan A, Zahid B, Ahmad S, Gul Z. Pancytopenia in children: A 6-year spectrum of patients admitted to Pediatric Department of Rehman Medical Institute, Peshawar. Pak J Med Sci. 2013 Sep;29(5):1153-7. doi: 10.12669/pjms.295.3865.

    PubMed 24353710
  • Jain A, Naniwadekar M. An etiological reappraisal of pancytopenia - largest series reported to date from a single tertiary care teaching hospital. BMC Hematol. 2013 Nov 6;13(1):10. doi: 10.1186/2052-1839-13-10.

    PubMed 24238033
  • Gnanaraj J, Parnes A, Francis CW, Go RS, Takemoto CM, Hashmi SK. Approach to pancytopenia: Diagnostic algorithm for clinical hematologists. Blood Rev. 2018 Sep;32(5):361-367. doi: 10.1016/j.blre.2018.03.001. Epub 2018 Mar 5.

    PubMed 29555368
  • Takeshima M, Ishikawa H, Kitadate A, Sasaki R, Kobayashi T, Nanjyo H, Kanbayashi T, Shimizu T. Anorexia nervosa-associated pancytopenia mimicking idiopathic aplastic anemia: a case report. BMC Psychiatry. 2018 May 25;18(1):150. doi: 10.1186/s12888-018-1743-6.

    PubMed 29801443

Questions about this trial

What is this clinical trial studying?

An observational study of Pancytopenia, run by Assiut University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 26 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact zakria younes mohammed, resident doctor (01121224119, zakriaessemy@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

percentage of aplastic anemia among other causes of pancytopenia in childern presented to assiut university childern hospital with abnormal CBC (time frame: one year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05473650, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jul 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in